Journal of Virology · 2020 · 16 citations · 29 references
Veterinary MedicineImmunologyInfectious DiseasesImmunizationVaccinologyVirologyAntiviral ImmunityDna VaccinesRecombinant Protein VaccinesSubunit VaccinesVaccinationViral VaccinesCoronavirus VaccinesCross-protective ImmunityGlycoprotein VaccinesPrime-boost Immunization RegimensPrime-boost Vaccination RegimensReceptor Binding Domain VaccinesSpike Glycoprotein BindingVaccine Strain Development
Coronavirus is an RNA virus with a higher mutation rate than DNA viruses. Therefore, a mutation in S-protein, which mediates viral infection by binding to a human cellular receptor, is expected to cause difficulties in vaccine development. Given that DNA-protein vaccines promote stronger cell-mediated immune responses than protein-only vaccination, we immunized mice with various combinations of DNA priming and protein boosting using the S-subunit sequences of the MERS-CoV EMC/2012 strain. We demonstrated a cross-protective effect against wild-type KOR/KNIH/002, a strain with two mutations in the S amino acids, including one in its RBD. The vaccine also provided cross-neutralization against 15 different S-pseudotyped viruses. These suggested that a vaccine targeting one variant of S can provide cross-protection against multiple viral strains with mutations in S. The regimen of DNA priming/Protein boosting can be applied to the development of other coronavirus vaccines.
29
Berend‐Jan Bosch, Ruurd van der Zee, Cornelis A. M. de Haan et al. · Journal of Virology · 2003 · 1.6K citations · Full text
Luigi Naldini, Ulrike Blömer, Fred H. Gage et al. · Proceedings of the National Academy of Sciences · 1996 · 1.5K citations · Full text